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Abstract
Introduction
• Alzheimer’s disease is defined as a chronic neurodegenerative 
disorder that is seen primarily in adults who are older than 65
• Currently, there is no cure for Alzheimer’s disease and current 
treatment options have many side effects. The hope with early 
detection is to give patients a better quality of life with the 
initiation of early treatment. 
• With each research analysis, the research’s strengths, 
weaknesses, and findings was compiled into meaningful 
conclusions
• This research will enable clinicians and medical facilities to be 
well versed in the various screening techniques available and 
be able to provide better care to their patients
Research Questions
Literature Review Applicability to Clinical 
Practice
Acknowledgements 
Alzheimer’s disease is a neurodegenerative disease that 
affects more than 55 million Americans. By the year 2050, 
experts project this disease will have increased three fold. 
Many screening techniques have been investigated to detect 
this disease early and begin treatment to slow its progression. 
The purpose of this study was to explore which medical 
modalities are the most effective for screening of Alzheimer’s 
disease. This literature review includes three databases, 
including PubMed, CINHAL, and Cochrane Database of 
Systematic Reviews. Topics that were researched include: 
cognitive screening tests, neuroimaging, laboratory diagnostic 
testing, DNA, and combined studies. All resources were 
published within the last ten years. Limitations and strengths 
were considered within each modality. In each category, the 
following were found to be the most effective in screening for 
Alzheimer’s disease: cognitive screening tests: MOST and 
MoCA testing; neuroimaging: PET scanning; laboratory 
diagnostic testing: biomarkers; DNA: DNA methylation and 
APOE genotyping; and combined studies: PET scanning. This 
review demonstrates that there are many screening 
modalities available to providers. This allows providers to 
choose their screening technique based on their site’s 
availability, provider preference, and cost.  
• What are the most effective screening options in the detection of 
Alzheimer’s disease?
• What limitations exist in these screening techniques?
• What are the benefits in the different screening techniques?
Cognitive Screening Test
• Clinosky and Clinosky (2010) investigated whether integration of 
3-word recall, list memory, clock drawing, and time orientation 
into the Memory Orientation Screening Tests (MOST) would be a 
more accurate means of screening for Alzheimer’s disease 
compared to Mini-Cog screening test and the Mini-Mental State 
Examination (MMSE)
• Freitas, Simoes, Alves, and Santana (2013) conducted a study 
to determine whether the Montreal Cognitive Assessment 
(MoCA) or the MMSE, was a better screening tool for cognitive 
decline
• Nakashima et al. (2015) designed a study to find if there is a 
correlation between regional cerebral blood flow and types of 
errors on the Clock Drawing Test in Alzheimer’s patients
Neuroimaging
• Fu et al. (2014) compared the (18) F-FDG PET scanner and the 
“dual biomarker” (11) C-PIB PET [(11) C-pPIB and amyloid PIB 
((11) C-aPIB)] for a screening of Alzheimer’s disease, patients 
with mild cognitive impairment, and patients that were cognitively 
“normal”
• Rabinovici et al. (2011) compared PET scanning with amyloid 
ligand Pittsburgh compound B (PiB-PET) to flouorodeoxyglucose 
(FDG-PET) in discriminating between frontotemporal lobar 
degeneration and Alzheimer disease
• Smailagic et al. (2015) investigated different studies regarding 
the accuracy of the F-FDG PET scan in identification of patients 
with mild cognitive impairment who would progress to 
Alzheimer’s dementia or other types of dementia
Laboratory Diagnostic Testing
• Burnham et al. (2016) investigated whether high or low 
neocortical beta-amyloid proteins (NAB) could predict a patient’s 
risk of development of Alzheimer’s disease within a 54-month 
period
• Mattsson et al. (2016) designed a study to test whether there is a 
correlation between plasma tau and Alzheimer’s disease
• O’Bryant et al. (2011) designed a study to investigate the 
relationship between serum biomarker proteins and Alzheimer’s 
disease
• Vemuri et al. (2017) identified 430 patients (age greater than 60) 
that were from the Mayo Clinic Study of Aging. Researchers 
wanted to investigate whether there is a correlation between 
patients with comorbidities and neurodegeneration
DNA
• Bollati et al. (2011) explored whether there is a relationship 
between DNA methylation and Alzheimer’s disease
• Kennedy, Cutter, and Schneider (2014) tested the apolipoprotein 
E epsilon4 genotype as a means of inclusion or exclusion in 
clinical trials for Alzheimer’s disease
Combined Studies
• Bateman et al. (2012) performed a longitudinal study 
investigating beta-amyloid CSF, PET scanning, tau proteins in 
CSF, and MMSE as a means for screening of Alzheimer’s 
disease 
• Palmqvist et al. (2015) compared the accuracy of CSF 
biomarkers to amyloid PET scanning in diagnosing early-stage 
Alzheimer’s disease
• This research proves that there are different medical modalities 
that can be used for screening of Alzheimer’s disease both in 
rural and urban communities
• Each screening test varies in the time it takes undergo the 
study, and the time it takes to obtain results
– Cognitive screening tests would be considered the fastest of 
the screening techniques discussed
• Clinicians should be well-versed on the screening techniques 
that they have available, and be able to interrupt the results
• With early detection of this disease, implementation of 
treatments can begin and slow the disease progression
• I would like to thank Dawn Hackman, MS, AHIP; Dr. Marilyn G. 
Klug, PhD, Associate Professor; Daryl Seig, PA-C; Julie Solberg, 
PA-C; Valorie Tuseth, FNP; Jeanmarie Dahl, PA-S; Larissa 
Haug, PA-S; Breanna Privratsky, PA-S; and Kate Walen Suda, 
PA-S for all the time and teachings that you provided during this 
process. I would also like to thank my husband and my family for 
all their love and support. My success of this project stems from 
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Statement of the Problem
• A key issue with researching Alzheimer’s disease is its difficulty 
to diagnose
• Without fulling understanding the disease, how can practitioners 
provide effective care and treatment?
• To date, there is no known screening test that has been shown 
to detect this disease with 100% accuracy
References
•Alzheimer’s Association. (2017). Chicago, IL. Retrieved June 30, 2017, from  https://www.alz.org/facts/  
•Bateman, R. J., Chengjie, X., Tammie, L. S., Benzinger, M. D., Fagan, A. M., Goate, A., . . . Morris, J. C. 
(2012). Clinical and biomarker changes in dominantly inherited  Alzheimer’s disease. The New England 
Journal of Medicine, 367(9), 795-804. doi:  10.1056/NEJMoa1202753  
•Bollati, V., Galimberti, D., Pergoil, L., Dalla Valle, E., Barretta, F., Cortini F., . . . Baccarelli, A. (2011). 
DNA methylation in repetitive elements and Alzheimer disease. Brain, Behavior, and Immunity, 25(6), 
1078-83. doi: 10.1016/j.bbi.2011.01.017  
•Burnham, S. C., Rowe, C. C., Baker, D., Bush, A. I., Doecke, J. D., Faux, N. G., . . . Villemagne,   V. L. 
(2016). Predicting Alzheimer disease from a blood-based biomarker profile: A 54  month follow up. 
Neurology, 87(11), 1093-1101. doi: 10.1212/WNL.0000000000003094  
•Clinosky, M. I. & Clinosky E. (2010). Development and validation of the Memory Orientation Screening 
Test (MOST): A better screening test for dementia. American Journal of Alzheimer’s Disease & Other 
Dementias, 25(8), 650-656. doi: 10.1177/1533317510386216  
•DynamedPlus. (2017). Alzheimer dementia. Ipswich MA: EBSCO. Retrieved from 
https://www.dynamed.com/topics/dmp~AN~T114193/Alzheimer-dementia 
•Freitas, S., Simoes, M. R., Alves L., & Santana, I. (2013). Montreal Cognitive Assessment:   validation 
study for mild cognitive impairment and Alzheimer disease. Alzheimer Disease & Associated Disorders, 
27(1), 37-43. doi: 10.1097/WAD.0b013e3182420bfe  
•Fu, L., Liu, L., Zhang, J., Xu, B., Fan, Y., & Tian, J. (2014). Comparison of dual-biomarker PIB-PET and 
dual-tracer PET in AD diagnosis. European Radiology, 24(11), 2800-2809. dio: 10.1007/s00330-014-
3311-x 
•Jin, Li, & Robertson. (2011). DNA Methylation. Genes Cancer, 2(6), 607-617. 
dio:10.1177/1947601910393957
•Kennedy R. E., Cutter G. R., & Schneider, L. S. (2014). Effect of APOE genotype status on   targeted 
clinical trials outcomes and efficiency in dementia and mild cognitive   impairment resulting from 
Alzheimer’s disease. Alzheimer’s and Dementia: The Journal  of the Alzheimer’s Association, 10(3), 349-
50. doi: 10.1016/j.jalz.2013.03.003  
•Mattsson, N., Zetterberg, H., Janelidze, S., Insel, P., Andreasson, U., Stomrud, E., . . . Biennow, K. 
(2016).  Plasma tau in Alzheimer disease. Neurology, 87(17), 1827-1835. dio:  
10.1212/WNL.0000000000003246  
•Nakashima, H., Umegaki, H., Makino, T., Kato, K., Abe, S., Suzuki, Y., & Kuzuya, M. (2015).  
Neuroanatomical correlates of error types on the clock drawing test in Alzheimer’s   disease patients. 
Geriatrics & Gerontology International, 16(7), 777-784. dio: 10.1111/ggi.12550  
•Nasreddine, Z. (2018). Montreal Cognitive Assessment (MoCA) [Online image]. Retrieved from 
mocatest.org
•O’Bryant, S. E., Xiao, G., Barber R., Huebinger R., Wilhelmsen K., Edwards M., . . .  Diaz  Arrastia, R., 
(2011). A blood-based screening tool for Alzheimer’s disease that spans   serum and plasma: Findings 
from TARC and ADNI. Plos One, 6(12). doi: 10.1371/journal.pone.0028092  
•Palmqvist, S., Zetterberg, H., Mattsson, N., Johansson, P., Minthon, L., Blennow, K., . . . Hansson, O. 
(2015). Detailed comparison of amyloid PET and CSF biomarkers for   identifying early Alzheimer’s 
disease. Neurology, 85(14), 1240-1249. doi: 10.1212/WNL.0000000000001991  
•Rabinovici, G. D., Rosen, H. J., Alkalay, A., Kornak, J., Furst A. J., Agarwal, N., . . . Jagust, W. J. (2011). 
Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.  Neurology, 77(23), 2034-42. doi: 
10.1212/WNL.0b013e31823b9c5e 
•Smailagic, N., Vacante, M., Hyde, C., Martin, S., Ukoumunne, O., & Sachpekidis, C. (2015). F FDG PET 
scan for early prediction of developing Alzheimer’s disease or other dementia   in people with mild 
cognitive impairment (MCI). Cochrane Database of Systematic  Reviews, 1. doi: 
10.1002/14651858.CD010632.pub2  
•Tan, L., Herrmann N., Mainland B., & Shaulman, K. (2015). Can clock drawing differentiate  Alzheimer’s 
disease from other dementias? International Psychogeriatric, 27(10), 1649-1660. doi: 
10.1017/S1041610215000939  
•Vemuri, P., Lesnick T., Przybelski, S., Knopman D., Lowe, V., Graff-Radford, J., . . . Jack, C. R. (2017). 
Age, vascular health, and Alzheimer’s disease biomarkers in an elderly sample. doi: 10.1002/ana.25071
Discussion
Cognitive Screening Test
• MOST and the MoCA should be used as cognitive screening 
tests for Alzheimer’s disease in a clinical setting (Clinosky and 
Clinosky, 2010 & Freitas, Simoes, Alves, and Santana, 2013) 
Clock drawing was not deemed an adequate method
Neuroimaging
• Dual screening PET scanning has potential as a means of 
screening in the future for Alzheimer’s disease (Fu et al., 2014 
& Rabinovici et al., 2011). The FDG, however, cannot predict 
whether a patient will progress to Alzheimer’s disease 
(Smailagic et al., 2015)  
Laboratory Diagnostic Testing
• There are inconsistent conclusions being made regarding beta-
amyloid proteins and tau proteins as a means of detection of 
Alzheimer’s disease. In addition, O’Bryant et al. (2011) were 
able to correlate eleven biomarker proteins to Alzheimer’s 
disease in the patient’s serum and plasma. Vemuri et al. (2017) 
concluded that vascular health had a direct and indirect impact 
on neurodegeneration. This relationship, nevertheless, needs to 
be investigate further according to the researchers
DNA
• Bollati et al. (2011) found that patients that had higher levels of 
LINE-1 methylation performed better on the MMSE. Kennedy, 
Cutter, and Schneider (2014) concluded that patients that were 
APOE epsilon4 carriers had more cognitive impairment and 
faster decline than those that had the APOE epsilon genotype 
only
Combined Studies
• Bateman et al. (2012) found that the concentrations of the beta-
amyloid in CSF declined 25 years before the onset of 
symptoms. Because the use of beta-amyloid proteins as a 
screening technique has found to be questionable, as shown in 
laboratory diagnostic testing conclusions, this conclusion should 
be researched further
• Palmqvist et al. (2015) found that both CSF biomarkers and 
amyloid PET scanning could be used in the identification of 
early Alzheimer’s disease. The research of O’Bryant et al. 
(2011) investigated the biomarkers in serum, versus the 
medium of CSF in this research. The use of medium may or 
may not affect the validity of the biomarkers in detection of 
Alzheimer’s disease. Further research needs to be considered  
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